AnaptysBio, Inc. Common Stock
ANABAnaptysBio, Inc. (ANAB) is a biotechnology company focused on developing therapeutic antibodies for immune-related conditions. Founded in 2005 and based in San Diego, California, the company utilizes innovative antibody discovery and engineering technologies to create novel biologics targeting inflammatory and immuno-oncology diseases. Its pioneering platform aims to address unmet medical needs through antibody therapeutics.
Company News
GSK's subsidiary Tesaro has filed a lawsuit against AnaptysBio in Delaware Chancery Court, alleging breach of a license agreement for the cancer drug Jemperli, and seeking to protect its royalty rights.
AnaptysBio filed a legal complaint in Delaware Chancery Court against Tesaro and GSK, alleging material breaches of their Collaboration Agreement, specifically related to PD-1 antagonist research and commercial efforts for the drug Jemperli.
AnaptysBio, a clinical-stage biotech company, has seen its stock price rise recently. A positive research note from Guggenheim analyst Yatin Suneja, who reiterated a buy rating and $75 price target, cites an upcoming phase 2 clinical trial readout for the company's atopic dermatitis drug and Sanofi's financial involvement as reasons for optimism.
Repligen (RGEN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
